miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer

Xiancai Ge1, Haiyan Cui2, Yanbing Zhou3

  • 1Department of General Surgery, 401 Hospital of People's Liberation Army, Qingdao, Shandong 266000, P.R. China.

Molecular Medicine Reports
|November 21, 2017
PubMed

Insights

MicroRNA-320a acts as a tumor suppressor in gastric cancer (GC) by inhibiting growth and enhancing cisplatin sensitivity. It targets ADAM10, suggesting a potential therapeutic axis for GC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) play crucial roles in gastric cancer (GC) pathogenesis, acting as either tumor suppressors or oncogenes.
  • The specific role and mechanism of microRNA (miR)-320a in GC are not fully understood.
  • Gastric cancer remains a significant global health challenge, necessitating novel therapeutic targets.

Purpose of the Study:

  • To elucidate the function and mechanism of miR-320a in gastric cancer.
  • To identify the direct target of miR-320a in GC.
  • To investigate the therapeutic potential of the miR-320a/ADAM10 axis in GC.

Main Methods:

  • Gain- and loss-of-function analyses using miRNA mimics and inhibitors in GC cells.
  • In vitro assays including colony formation, proliferation, and cisplatin-sensitivity tests.
  • In vivo xenograft models, bioinformatics, luciferase reporter assays, western blotting, and analysis of primary tumor samples.

Main Results:

  • miR-320a expression was significantly reduced in GC cells.
  • Ectopic miR-320a expression inhibited GC cell growth (in vitro and in vivo) and increased cisplatin sensitivity.
  • ADAM metallopeptidase domain 10 (ADAM10) was identified as a direct target of miR-320a; its knockdown mimicked miR-320a's tumor-suppressive effects.
  • A negative correlation between miR-320a and ADAM10 expression was observed in GC tumors.

Conclusions:

  • miR-320a functions as a tumor suppressor in gastric cancer progression.
  • The miR-320a/ADAM10 axis represents a potential therapeutic target for gastric cancer.
  • Modulating miR-320a or ADAM10 could offer novel treatment strategies for GC.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K